

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6147290

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	SECURITY INTEREST	
CONVEYING PARTY DATA		
	Name	Execution Date
	ADC THERAPEUTICS SA	05/19/2020
RECEIVING PARTY DATA		
Name:	DEERFIELD PARTNERS, L.P.	
Street Address:	780 THIRD AVENUE, 37TH FLOOR	
City:	NEW YORK	
State/Country:	NEW YORK	
Postal Code:	10017	
PROPERTY NUMBERS Total: 1		
Property Type	Number	
Patent Number:	9919056	
CORRESPONDENCE DATA		
Fax Number:	(608)662-1276	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	6086621277	
Email:	maschur@casimirjones.com	
Correspondent Name:	MELISSA E. KOLOM	
Address Line 1:	2275 DEMING WAY	
Address Line 2:	SUITE #310	
Address Line 4:	MIDDLETON, WISCONSIN 53562	
ATTORNEY DOCKET NUMBER:	MEWB-35696.256	
NAME OF SUBMITTER:	MELISSA E. KOLOM	
SIGNATURE:	/Melissa E. Kolom/	
DATE SIGNED:	06/10/2020	
Total Attachments: 114		
source=ADC-Deerfield-Pledge#page1.tif		
source=ADC-Deerfield-Pledge#page2.tif		
source=ADC-Deerfield-Pledge#page3.tif		
source=ADC-Deerfield-Pledge#page4.tif		
source=ADC-Deerfield-Pledge#page5.tif		

source=ADC-Deerfield-Pledge#page6.tif
source=ADC-Deerfield-Pledge#page7.tif
source=ADC-Deerfield-Pledge#page8.tif
source=ADC-Deerfield-Pledge#page9.tif
source=ADC-Deerfield-Pledge#page10.tif
source=ADC-Deerfield-Pledge#page11.tif
source=ADC-Deerfield-Pledge#page12.tif
source=ADC-Deerfield-Pledge#page13.tif
source=ADC-Deerfield-Pledge#page14.tif
source=ADC-Deerfield-Pledge#page15.tif
source=ADC-Deerfield-Pledge#page16.tif
source=ADC-Deerfield-Pledge#page17.tif
source=ADC-Deerfield-Pledge#page18.tif
source=ADC-Deerfield-Pledge#page19.tif
source=ADC-Deerfield-Pledge#page20.tif
source=ADC-Deerfield-Pledge#page21.tif
source=ADC-Deerfield-Pledge#page22.tif
source=ADC-Deerfield-Pledge#page23.tif
source=ADC-Deerfield-Pledge#page24.tif
source=ADC-Deerfield-Pledge#page25.tif
source=ADC-Deerfield-Pledge#page26.tif
source=ADC-Deerfield-Pledge#page27.tif
source=ADC-Deerfield-Pledge#page28.tif
source=ADC-Deerfield-Pledge#page29.tif
source=ADC-Deerfield-Pledge#page30.tif
source=ADC-Deerfield-Pledge#page31.tif
source=ADC-Deerfield-Pledge#page32.tif
source=ADC-Deerfield-Pledge#page33.tif
source=ADC-Deerfield-Pledge#page34.tif
source=ADC-Deerfield-Pledge#page35.tif
source=ADC-Deerfield-Pledge#page36.tif
source=ADC-Deerfield-Pledge#page37.tif
source=ADC-Deerfield-Pledge#page38.tif
source=ADC-Deerfield-Pledge#page39.tif
source=ADC-Deerfield-Pledge#page40.tif
source=ADC-Deerfield-Pledge#page41.tif
source=ADC-Deerfield-Pledge#page42.tif
source=ADC-Deerfield-Pledge#page43.tif
source=ADC-Deerfield-Pledge#page44.tif
source=ADC-Deerfield-Pledge#page45.tif
source=ADC-Deerfield-Pledge#page46.tif
source=ADC-Deerfield-Pledge#page47.tif
source=ADC-Deerfield-Pledge#page48.tif
source=ADC-Deerfield-Pledge#page49.tif
source=ADC-Deerfield-Pledge#page50.tif
source=ADC-Deerfield-Pledge#page51.tif
source=ADC-Deerfield-Pledge#page52.tif
source=ADC-Deerfield-Pledge#page53.tif

source=ADC-Deerfield-Pledge#page54.tif
source=ADC-Deerfield-Pledge#page55.tif
source=ADC-Deerfield-Pledge#page56.tif
source=ADC-Deerfield-Pledge#page57.tif
source=ADC-Deerfield-Pledge#page58.tif
source=ADC-Deerfield-Pledge#page59.tif
source=ADC-Deerfield-Pledge#page60.tif
source=ADC-Deerfield-Pledge#page61.tif
source=ADC-Deerfield-Pledge#page62.tif
source=ADC-Deerfield-Pledge#page63.tif
source=ADC-Deerfield-Pledge#page64.tif
source=ADC-Deerfield-Pledge#page65.tif
source=ADC-Deerfield-Pledge#page66.tif
source=ADC-Deerfield-Pledge#page67.tif
source=ADC-Deerfield-Pledge#page68.tif
source=ADC-Deerfield-Pledge#page69.tif
source=ADC-Deerfield-Pledge#page70.tif
source=ADC-Deerfield-Pledge#page71.tif
source=ADC-Deerfield-Pledge#page72.tif
source=ADC-Deerfield-Pledge#page73.tif
source=ADC-Deerfield-Pledge#page74.tif
source=ADC-Deerfield-Pledge#page75.tif
source=ADC-Deerfield-Pledge#page76.tif
source=ADC-Deerfield-Pledge#page77.tif
source=ADC-Deerfield-Pledge#page78.tif
source=ADC-Deerfield-Pledge#page79.tif
source=ADC-Deerfield-Pledge#page80.tif
source=ADC-Deerfield-Pledge#page81.tif
source=ADC-Deerfield-Pledge#page82.tif
source=ADC-Deerfield-Pledge#page83.tif
source=ADC-Deerfield-Pledge#page84.tif
source=ADC-Deerfield-Pledge#page85.tif
source=ADC-Deerfield-Pledge#page86.tif
source=ADC-Deerfield-Pledge#page87.tif
source=ADC-Deerfield-Pledge#page88.tif
source=ADC-Deerfield-Pledge#page89.tif
source=ADC-Deerfield-Pledge#page90.tif
source=ADC-Deerfield-Pledge#page91.tif
source=ADC-Deerfield-Pledge#page92.tif
source=ADC-Deerfield-Pledge#page93.tif
source=ADC-Deerfield-Pledge#page94.tif
source=ADC-Deerfield-Pledge#page95.tif
source=ADC-Deerfield-Pledge#page96.tif
source=ADC-Deerfield-Pledge#page97.tif
source=ADC-Deerfield-Pledge#page98.tif
source=ADC-Deerfield-Pledge#page99.tif
source=ADC-Deerfield-Pledge#page100.tif
source=ADC-Deerfield-Pledge#page101.tif

source=ADC-Deerfield-Pledge#page102.tif
source=ADC-Deerfield-Pledge#page103.tif
source=ADC-Deerfield-Pledge#page104.tif
source=ADC-Deerfield-Pledge#page105.tif
source=ADC-Deerfield-Pledge#page106.tif
source=ADC-Deerfield-Pledge#page107.tif
source=ADC-Deerfield-Pledge#page108.tif
source=ADC-Deerfield-Pledge#page109.tif
source=ADC-Deerfield-Pledge#page110.tif
source=ADC-Deerfield-Pledge#page111.tif
source=ADC-Deerfield-Pledge#page112.tif
source=ADC-Deerfield-Pledge#page113.tif
source=ADC-Deerfield-Pledge#page114.tif

IP Pledge Agreement

dated 19 May 2020

by and between

ADC Therapeutics SA (the Pledgor)
Biopôle
route de la Corniche 3 B
1066 Epalinges
Switzerland

and

Deerfield Partners, L.P. (the Security Agent)
780 Third Avenue, 37th Floor
New York, NY 10017
USA

as security agent and pledgee, acting for itself and as direct representative (*direkter Stellvertreter*) in the name and for the account of all other Secured Parties

and

the Secured Parties (the Pledgees)

represented for all purposes hereof by the Security Agent as direct representative (*direkter Stellvertreter*)

regarding

the pledge of all the Intellectual Property and Related Assets of the Pledgor

Table of Contents

1.	Definitions and construction	4
1.1.	Definitions.....	4
1.2.	Construction	8
2.	Pledge and Pledgor's obligations	9
2.1.	Undertaking to pledge	9
2.2.	Effecting of the Pledge.....	9
2.3.	Registration.....	9
3.	Intellectual Property.....	10
3.1.	Right to use Intellectual Property.....	10
3.2.	Information duties	11
4.	Representations and warranties	12
5.	Further undertakings of the Pledgor	13
6.	Enforcement.....	15
7.	Conditional assignment	16
8.	Allocation and application of proceeds.....	17
9.	Additional Pledges; authorisation.....	17
10.	Continuing Security; effectiveness of collateral	18
11.	Release of Pledged Assets	19
12.	Reinstatement and avoidance of payments	19
13.	Miscellaneous	20
13.1.	Costs and expenses.....	20
13.2.	Waivers and amendment	20
13.3.	Assignment or transfer	20
13.4.	Notices	21
13.5.	Severability	21
13.6.	Counterparts.....	21

14. Law and jurisdiction	21
Schedule 1: Existing Intellectual Property	24
Schedule 2a: Form of Notification Letter to the World Institute of Intellectual Property Organisation	110
Schedule 2b: Form of Notification Letter to Swiss Federal Institute of Intellectual Property (trademarks)	111
Schedule 2c: Form of Notification Letter to Swiss Federal Institute of Intellectual Property (patents)	112

WHEREAS

- A. On 24 April 2020, a facility agreement has been entered into between, amongst others, ADC Therapeutics SA as Borrower, the Lenders named therein and Deerfield Partners, L.P. as Agent (all as defined therein) (the **Facility Agreement**).
- B. It is a condition under the Facility Agreement that, as Security (as defined below) for the due and punctual fulfilment of the Secured Obligations (as defined below), the Pledgor grants a pledge to the Pledgees over the Pledged Assets (as defined below).
- C. In accordance with section 9.13 (*Agent*) of the Facility Agreement and more specifically in accordance with paragraph (b) of section 9.13 (*Agent*) of the Facility Agreement, each Secured Party has appointed the Security Agent to enter into this Agreement for itself and for and on behalf of each other Secured Party as direct representative (*direkter Stellvertreter*) and to hold the Security hereby constituted as direct representative (*direkter Stellvertreter*) for itself and for all other Secured Parties.
- D. The Pledgor is willing to pledge the Pledged Assets to the Pledgees as provided herein.

NOW THEREFORE, the parties hereto (the **Parties**) agree as follows:

1. Definitions and construction
1.1. Definitions

Unless defined otherwise herein, capitalised terms and expressions used herein shall have the meaning ascribed to them in the Facility Agreement.

When used in this Agreement only, the following capitalised terms shall have the meaning assigned to them below:

Agreement means this IP pledge agreement and its schedules.

CC means the Swiss Civil Code (*Schweizerisches Zivilgesetzbuch*) dated 10 December 1907.

Clause means a clause of this Agreement.

CO means the Swiss Code of Obligations (*Schweizerisches Obligationenrecht*) dated 30 March 1911.

Collateral Rights means all rights, powers and remedies of the Security Agent or the Pledgees provided by this Agreement or by law.

DEBA means the Swiss Debt Collection and Bankruptcy Act (*Bundesgesetz über Schuldbetreibung und Konkurs*) dated 11 April 1889.

Declared Default means the occurrence of an Event of Default which has been accelerated in accordance with the terms of the Finance Documents.

Enforcement means the enforcement, foreclosure or any other kind of realisation of the Pledged Assets.

Facility Agreement has the meaning given to it in section A. of the preamble to this Agreement.

Finance Documents means the Facility Documents as defined in the Facility Agreement.

Group means the Pledgor and each of its Subsidiaries for the time being.

Intellectual Property means:

- (a) all rights, titles and interests it has under any copyright or other intellectual property law, including without limitation any copyrights in software, databases, other works or any computer programming code (in readable form) of any such software, databases or other work (the **Copyrights**), patents (the **Patents**), trademarks (the **Trademarks**) and domain names (the **Domain Names**), worldwide, owned as of the date hereof or acquired in the future by the Pledgor, in each case whether registered or not (including those as set-out in Schedule 1);
- (b) all pending or future applications for, and the rights to make applications for, any of those rights set forth in (a) above (where such

applications can be made), including, without limitation, the pending trademark applications as outlined in Schedule 1 of this Agreement;

- (c) all rights which have the same or similar effect or nature as or to those in (a) or (b) above or which would in any way prevent or hinder the use or exploitation of the matter to which they relate, in each case worldwide; and
- (d) in each case of (a), (b) and (c) except for any assets situated in England and Wales.

Pledge means a pledge pursuant to art. 899 et seq. CC of the Pledged Assets in accordance with the terms of this Agreement.

Pledged Assets means the Intellectual Property and Related Assets or any other security or asset that is to be or will be pledged to the Pledgees under this Agreement.

Pledgees means all existing Secured Parties as well as any future Secured Party which becomes a Pledgee pursuant to Clause 9(a) (*Additional Pledgees*;), but excluding any person which pursuant to Clause 9(a) (*Additional Pledgees*;) has ceased to be a Pledgee.

Pledgor has the meaning given to it on the cover page of this Agreement.

Related Assets means, all and any rights, claims or benefits in respect of or derived from the Intellectual Property, including without limitation, claims for damages or claims against an insurance provider in case of loss or damage to the Intellectual Property, to the extent such rights are assignable.

Secured Obligations means, all present and future obligations and liabilities (whether actual or contingent, whether owed jointly, severally or in any other capacity whatsoever) of the Pledgor (or any other member of the Group) to and towards the Secured Parties under and/or in connection with any Finance Document (including any convertible note or any similar instrument, in particular the Convertible Notes), together with any of the following matters relating to or arising in respect of those liabilities and obligations:

- (a) any refinancing, novation, deferral or extension;
- (b) any claim for damages or restitution; and

- (c) any claim as a result of any recovery by the Pledgor of a payment or discharge on the grounds of preference,

and any amounts which would be included in any of the above but for any discharge, non-provability or unenforceability of those amounts in any insolvency or other proceedings. The Secured Obligations shall include any obligation based on unjust enrichment (*ungerechtfertigte Bereicherung*) or tort (*Delikt*).

Secured Parties has the meaning given to it in the Facility Agreement.

Security means a mortgage, charge, pledge, lien or other security interest having a similar effect.

Security Agent has the meaning given to it on the cover page of this Agreement.

Selected Jurisdictions means: Australia, Canada, New Zealand, South Africa, United States of America, European Patent Office, Belgium, Czech Republic, Germany, Denmark, Estonia, Finland, France, Hungary, Ireland, Iceland, Luxembourg, Malta, Netherlands, Norway, Portugal, Sweden, Slovenia.

Subsidiary means in relation to any company, corporation or partnership, any company, corporation or partnership:

- (a) of which that person has direct or indirect control; and
- (b) of which a person has direct or indirect control or owns directly or indirectly more than 50 per cent. of the voting capital or similar right of ownership,

and for this purpose "control" means the direct or indirect ownership of a majority of the voting share capital or similar ownership rights of that entity, or the right or ability to determine the composition of a majority of the board of directors (or equivalent body) of such company, corporation or partnership or otherwise to direct the management of such entity whether by virtue of ownership of share capital, contract or otherwise.

Swiss Civil Procedure Code means the Swiss Federal Civil Procedure Code (*Zivilprozessordnung, ZPO*) dated 19 December 2008.

1.2. Construction

- (a) In this Agreement, section 1.2 of the Facility Agreement shall apply *mutatis mutandis* to this Agreement.
- (b) In addition, in this Agreement:
 - (i) references to any agreement or other document are references to such agreement or document as amended, restated, novated, supplemented, extended or replaced, from time to time, in accordance with its terms and includes any change in the purpose of, any extension of or any increase in any facility, any increase in any margin, or the addition of any new facility under that agreement or document;
 - (ii) references to Clauses and Schedules are references to clauses of and schedules to this Agreement;
 - (iii) words importing the plural shall include the singular and vice versa; and
 - (iv) "including" means "including without limitation", not limiting the term(s) to which the word relates to the example(s) thereafter mentioned; and
 - (v) unless the context requires otherwise, references herein to the Security Agent shall be read as references to the Security Agent acting for itself and as direct representative (*direkter Stellvertreter*) in the name and for the account of the other Pledgees.
- (c) If any terms of this Agreement are contradictory to the Facility Agreement, then the latter shall prevail and such contradiction shall not be considered a breach under this Agreement, it being understood that the validity, legality and enforceability of this Agreement shall not in any way be affected or impaired.

2. Pledge and Pledgor's obligations

2.1. Undertaking to pledge

The Pledgor hereby agrees to pledge to the Pledgees, directly represented by the Security Agent, acting for itself and as direct representative (*direkter Stellvertreter*) in the name and for the account of the other Pledgees, the Pledged Assets free and clear of any Security in favour of third parties and as continuing first ranking Security for the Secured Obligations.

2.2. Effecting of the Pledge

- (a) For the purposes of effecting the Pledge as described in Clause 2.1 (*Undertaking to pledge*), the Pledgor hereby pledges with immediate effect as per the date hereof all Pledged Assets to the Pledgees, directly represented by the Security Agent, acting for itself and as direct representative (*direkter Stellvertreter*) in the name and for the account of the other Pledgees, as a continuing first ranking Security, free and clear of any Security in favour of third parties in order to secure the Secured Obligations.
- (b) The Pledge of the Pledged Assets shall be effective as of the date hereof and shall be valid regardless of whether or not such Pledge can be registered and regardless of whether or not the Pledge is or will be registered with the competent registration organisation.

2.3. Registration

- (a) With respect to the Intellectual Property other than Domain Names, the Pledgor herewith (i) undertakes to notify the Pledge to the Swiss Federal Institute of Intellectual Property, all other competent trademark offices and authorities and/or third parties, as applicable, and to submit the Pledge for registration to the Swiss Federal Institute of Intellectual Property, trademark registers or any other registers, as applicable, of each Selected Jurisdiction within thirty (30) Business Days and make its best efforts to effect the registrations and (ii) authorizes the Security Agent to make any notifications and registrations in connection with the Pledge. For the purpose of 2.3 (a)(ii), the Pledgor shall within thirty (30)

Business Days from the date of this Agreement deliver to the Security Agent prepared and signed notification letters, inter alia, in the form as attached to in Schedules 2a, 2b and 2c as the case may be, or otherwise applicable and required as the case may be; the Pledgor shall, at the reasonable request of the Security Agent, further take all measures and acts and execute and deliver all written instruments and declarations required to perfect, protect and maintain the registration of such Pledge.

- (b) With respect to such Intellectual Property which the Pledgor does not hold exclusive ownership of, upon the Security Agent's request, the Pledgor will provide a consent letter in writing signed by each co-owner of such Intellectual Property acknowledging to and agreeing with the Pledge and the registration of the Pledge in the respective Intellectual Property register within fifteen (15) Business Days following the request of the Security Agent.
- (c) With respect to the Domain Names, the Pledgor herewith authorises the Security Agent to notify the Pledge to all competent offices, other authorities and/or third parties, as applicable, and to register the Pledge in Switzerland and any Selected Jurisdiction. Therefore, the Pledgor shall at its sole costs and expenses, promptly upon request of the Security Agent, prepare, sign and deliver to the Security Agent signed notification letters and/or any document otherwise applicable and provided by the Security Agent.
- (d) Paragraphs (a), (b) and (c) of this Clause 2.3 (*Registration*) shall apply *mutatis mutandis* in case the Pledgor acquires any additional Intellectual Property in Switzerland or any Selected Jurisdiction in the future, whether by registration, purchase or otherwise.

3. Intellectual Property

3.1. Right to use Intellectual Property

- (a) For so long as no Event of Default has occurred, the Pledgor shall retain, and the Security Agent, acting on its own behalf and on behalf of each Pledgee, hereby acknowledges that the Pledgor has and authorises and grants the Pledgor the sole and exclusive right and authority to use the

Pledged Assets at its sole discretion and for its own account in the course of business, subject to and in accordance with the Finance Documents. For the avoidance of doubt, other than as expressly set forth in the Finance Documents (including this Agreement), the Pledgor shall in no way or manner be limited in its use and exploitation of the Pledged Assets.

- (b) Upon and following the occurrence of an Event of Default,
 - (i) the Pledgor shall in no event take actions that could adversely affect (x) the validity and/or enforceability of the security interest created under this Agreement and/or (y) the value of the Pledged Assets; and
 - (ii) upon being notified by the Security Agent, the Pledgor shall no longer be entitled to use the Pledged Assets (including to grant, extend or otherwise amend licenses) without the prior written consent of the Security Agent.
- (c) Irrespective of and in addition to the foregoing, the Security Agent shall be entitled to revoke the power of attorney granted under paragraph (a) of this Clause at any time where an event or a circumstance makes a revocation necessary in the reasonable discretion of the Security Agent in order to perfect, maintain or protect the Security created under this Agreement and/or the Collateral Rights.

3.2. Information duties

- (a) On the date of this Agreement, the Pledgor shall provide the Security Agent with a list of the Intellectual Property as of the date hereof, in the form set out in Schedule 1.
- (b) The Pledgor shall provide the Security Agent, (i) on the date of this Agreement and then (ii) within one hundred and fifty (150) days after the end of each fiscal year of the Pledgor, or (iii) in any event as from an Event of Default which is continuing upon the Security Agent's request (acting reasonably), with correct, complete and up-to-date lists of Intellectual Property in the form set out in Schedule 1. Such lists of Intellectual Property are of declaratory nature and the Pledged Assets

are pledged irrespective of whether or not the Intellectual Property or the Pledged Assets have been or will be listed.

4. Representations and warranties

- (a) The Pledgor represents and warrants to the Security Agent acting for itself and as direct representative (*direkter Stellvertreter*) in the name and for the account of the other Pledgees as at the date hereof and during the subsistence of this Agreement as follows:
 - (i) it is the sole legal owner of the Intellectual Property and the Pledged Assets;
 - (ii) the Pledged Assets have not been assigned or pledged or otherwise encumbered and are free and clear of any Security (except as created under this Agreement and except Security permitted to exist under the Finance Documents) and/or any restriction on the ability to encumber, transfer or realise all or any part of the Pledged Assets;
 - (iii) all Pledged Assets have been validly created and, to the extent registration is possible, the registered Intellectual Property set out in Schedule 1 are properly registered in the name of the Pledgor with the competent registration organisation;
 - (iv) all details regarding the Intellectual Property set out in Schedule 1 are correct, accurate, complete and up-to-date;
 - (v) it is validly existing, has the power to enter into and perform its obligations under this Agreement and all consents, approvals and authorisations have been obtained to make the Pledge valid, binding and enforceable in accordance with the terms of this Agreement;
 - (vi) this Agreement constitutes legal and valid obligations, binding upon the Pledgor and is an effective Security over the Pledged Assets; and
 - (vii) no board's or shareholders' resolution (or similar resolution) of the Pledgor, has been passed or approved nor has any application been made with respect to the Pledgor in relation to bankruptcy,

voluntary or judicial liquidation, composition with creditors, suspension of payments, controlled management, general settlement with creditors, reorganisation or similar legal proceedings which would be likely have an adverse effect (in terms of value, enforceability or otherwise) on the Pledge and/or the Pledged Assets or any other right of the Security Agent or any other Pledgee under this Agreement.

- (b) The representations and warranties in this Clause 4 (*Representations and warranties*) shall be in addition to and not in lieu of the representations and warranties of the Pledgor in the other Finance Documents and are made by the Pledgor by reference to the facts and circumstances existing as of the date of this Agreement and are deemed to be repeated on, and by reference to the facts and circumstances then existing on, and as of any Disbursement Date and as of the date of each Perfection Certificate, from the date of this Agreement until the release of the Pledged Assets.

5. Further undertakings of the Pledgor

Without prejudice and in addition to the undertakings of the Pledgor or any other Loan Party under the Facility Agreement and any other Finance Document, the Pledgor hereby undertakes to the Security Agent and the Pledgees as follows:

- (a) to promptly execute and deliver at its own cost and expense all further instruments and documents, and take all further action, that the Security Agent may reasonably request or that are required as a matter of law, in order to (i) perfect, register (subject to Clause 2.3 (*Registration*)), protect, secure, maintain and enforce the Security created or contemplated by this Agreement, (ii) facilitate the exercise of the Security Agent's and Pledgees' Collateral Rights and (iii) enable the Security Agent and the other Pledgees to transfer and assign this Agreement or any rights or obligations hereunder (including the Security over the Pledged Assets) in accordance with Clause 13.3 (*Assignment or transfer*);
- (b) at its own expense, to enter into and procure the perfection of additional pledge or security agreements, if and to the extent that a Pledge of certain Related Assets requires as a matter of law, the

execution and perfection of a specific pledge or security agreement and/or any other action for such Related Assets;

- (c) except with the Security Agent's prior written consent or unless expressly permitted otherwise under the Finance Documents, not to:
 - (i) do, or permit to be done, anything which would adversely affect the priority, ranking, legality, validity and enforceability or value of the Security created or expressed to be created pursuant to this Agreement and/or the Collateral Rights,
 - (ii) enter into any legal instrument relating to, or granting any Security over, or dispose of, or assign its Pledged Assets, or
 - (iii) take any other action with respect to the Pledged Assets that would jeopardise any rights of the Security Agent and/or the Pledgees under the Pledge, or would jeopardise the Enforcement of the Pledged Assets;
- (d) to immediately notify the Security Agent of, and provide the Security Agent with all information relating to, any occurrence which has or would have an adverse effect on the Pledge and/or on the Pledged Assets (including any material infringement, misappropriation or dilution or threatened or suspected material infringement misappropriation or dilution of or any challenge to the validity of any such Intellectual Property owned by it) in order to allow the Security Agent to effectively ensure that the value and validity of the Pledge and/or the Collateral Rights is perfected and maintained;
- (e) immediately upon becoming aware of any litigation in respect of any Intellectual Property, to notify the Security Agent thereof and to provide the Security Agent with all information relating thereto. Upon the occurrence of an Event of Default, the Security Agent shall have the right, but not the obligation to give the Pledgor binding instructions or to join the Pledgor in any such litigation or, if permitted by law, to litigate on behalf of the Pledgor in case of a litigation in respect of the Intellectual Property; and
- (f) to take all legal and other actions which are necessary to safeguard the Security Agent's and the other Pledgees' rights under or in respect of the Pledged Assets.

6. Enforcement

- (a) Upon the occurrence of a Declared Default, the Security Agent (acting for itself and as direct representative (*direkter Stellvertreter*) in the name and for the account of the other Pledgees) shall be entitled (but not obliged), at its full discretion and without prior notice to the Pledgor or any other party, to:
 - (i) effect Enforcement by either (1) private realisation (*Privatverkauf*, including, to the extent legally permitted self-sale (*Selbsteintritt*) of the Pledged Assets or (2) enforcement proceedings pursuant to the DEBA under the exclusion of article 41 para 1^{bis} DEBA (waiver of the *beneficium excussionis realis*) and the Parties agree in advance that a "*Freihandverkauf*" shall be admissible;
 - (ii) act as Security Agent contracting in its own name and in the name of the Pledgees and on its own and their accounts or for the account of third persons in private or official Enforcement; and
 - (iii) apply all monies arising from the Pledged Assets as though they were the proceeds of an Enforcement under this Agreement.
- (b) Failure by the Security Agent or any Pledgee to sell Pledged Assets or to exercise any right or remedy shall not result in any liability of the Security Agent or any Pledgee and shall not prejudice any of the rights the Security Agent and the Pledgees may have under this Agreement or any other of the Finance Documents, nor be a waiver of any obligation of the Pledgor hereunder and/or thereunder.
- (c) Notwithstanding previous enforcement actions with respect to the Pledged Assets without formality or notice, the Security Agent retains the right at all times to take any measure it deems necessary or appropriate in accordance with the DEBA or any analogous provisions under applicable foreign law.
- (d) The Security Agent shall not be bound to enforce any other Security before enforcing the Security created by this Agreement.
- (e) The Security Agent shall be free to enforce all or only part of the Pledged Assets and to determine the order of enforcement into the Pledged Assets.

- (f) The Security Agent shall be entitled to enforce the Pledge in respect of all or only part of the Security. Such partial enforcement shall not affect the Pledge on the remaining Security.
- (g) The Pledgor agrees that the Security Agent can instruct a third party to conduct the Enforcement of the Pledge for its account.
- (h) In connection with an Enforcement under this Agreement, the Pledgor:
 - (i) waives any right of requesting that the Pledged Assets be realised before foreclosure in any of its other assets or before exercise of any other Security which may have been granted to the Security Agent and/or the other Secured Parties for the Secured Obligations;
 - (ii) shall at the request of the Security Agent fully co-operate with the Security Agent and use its best efforts in assisting the Security Agent with regard to the Enforcement; and
 - (iii) shall upon request of the Security Agent, provide the Security Agent free of charge with all information, records and documents that are required or requested for the purpose of enforcing this Agreement, in copy or, if necessary or requested by the Security Agent, in original.

7. Conditional assignment

To the extent that the Pledge on the Intellectual Property and the Related Assets cannot be perfected and/or enforced under Clauses 2 (*Pledge and Pledgor's obligations*), 5 (*Further undertakings of the Pledgor*) or 6 (*Enforcement*) under applicable law, this Agreement, upon the occurrence of an Event of Default, constitutes a conditional assignment pursuant to art. 164 et seq. CO by way of security (*Sicherungscession*) and/or the transfer of title by way of security (*Sicherungsübereignung*), as the case may be, of said Intellectual Property and Related Assets from the Pledgor to the Security Agent, acting for itself and as a fiduciary for the account of each Secured Party, allowing the Security Agent, to perfect (i) private realisation or (ii) institute enforcement proceedings each as stated in Clause 6 (*Enforcement*).

8. Allocation and application of proceeds

Any proceeds received hereunder by a Secured Party, in particular any proceeds received under Clause 6 (*Enforcement*), shall be applied in accordance with the Finance Documents.

9. Additional Pledges; authorisation

- (a) The Pledgor acknowledges and agrees that the Security Agent is entering into this Agreement acting as representative (*direkter Stellvertreter*) pursuant to section 9.13 (*Agent*) of the Facility Agreement and more specifically in accordance with paragraph (b) of section 9.13 (*Agent*) of the Facility Agreement for itself and as direct representative (*direkter Stellvertreter*) in the name and for the account of the other Pledges and that for such purpose upon an additional person becoming a Secured Party under the Facility Agreement, such new Secured Party shall automatically become a Pledgee hereunder and any Secured Party which has ceased to be a Secured Party shall automatically cease to be a Pledgee hereunder.
- (b) The Pledgor authorises the Security Agent to be its authorised representative, and in its name, on its behalf and as its act and deed to execute, deliver and perfect all documents and do all things that the Security Agent may consider to be requisite for carrying out any obligation imposed on the Pledgor under this Agreement or exercising any of the rights conferred on the Security Agent or the Pledges by this Agreement or by law, in particular in connection with a private realisation (*Private Verwertung*, including, without limitation, self-sale (*Selbsteintritt*)), provided that such authorisation granted hereunder shall not be exercisable unless:
 - (i) a Declared Default has occurred; or
 - (ii) the Pledgor has materially failed to comply with a written request to fulfil a further assurance or perfection or other obligation within any grace period applicable thereto.

10. Continuing Security; effectiveness of collateral

- (a) The Pledge constitutes a continuing Security which shall be cumulative, in addition to and independent of every other Security which the Security Agent or any other Secured Party may at any time hold for the Secured Obligations or any rights, powers and remedies provided by law.
- (b) The Security expressed to be created under this Agreement shall not be affected in any way by any variation, amendment, restatement, novation, transfer (including by way of novation), extension, compromise or release of any or all of the Secured Obligations or the Finance Documents or of any other Security from time to time.
- (c) The Pledgor agrees that no rights and claims shall pass to or otherwise arise for the benefit of the Pledgor by subrogation (*gesetzlicher Übergang von Forderungen und Rechten*) or otherwise, including any recourse claims, indemnification claims, claims arising from unjust enrichment (*ungerechtfertigte Bereicherung*) and any right to demand the assignment and/or transfer of any Secured Obligations and/or Security, against any obligor, grantor of Security or Secured Party (as the case may be) which the Pledgor may (but for this paragraph) be entitled to as a result of:
 - (i) a payment or repayment by the Pledgor of any debt of any other obligor under any of the Finance Documents; or
 - (ii) in case of Enforcement of the Pledge (or any part thereof).

The Pledgor furthermore undertakes (i) not to exercise (*pactum de non petendo*), and not to purport to exercise, any such rights and claims which may pass to it or otherwise arise for its benefit notwithstanding this paragraph or would pass to it or otherwise arise for its benefit but for this paragraph and (ii) to immediately pay or transfer to the Security Agent any payment or distribution or benefit of Security received by it contrary to this paragraph or as otherwise directed by the Security Agent under this paragraph.

11. Release of Pledged Assets

- (a) Subject to Clause 12 (*Reinstatement and avoidance of payments*) below, at the request and at the cost of the Pledgor, the Security Agent shall release and discharge the Pledged Assets from the Pledge upon full and final discharge of the Secured Obligations or as otherwise expressly permitted under the Finance Documents.
- (b) Upon release and discharge pursuant to paragraph (a) of this Clause, the Pledge created pursuant to this Agreement shall automatically terminate and the Pledged Assets then remaining and not previously applied against the Secured Obligations shall be released and returned by the Security Agent (or such other Pledgee, as the case may be) to the Pledgor (all at the sole cost of the Pledgor).
- (c) The Security Agent and the other Pledgees will not make or shall not be deemed to have made any representation or warranty, whether express or implied, with respect to any Pledged Assets so delivered, except that any such Pledged Assets shall be delivered to the Pledgor free and clear of any encumbrance or other third party right granted by the Security Agent or any other Pledgee.

12. Reinstatement and avoidance of payments

If any payment in respect of Secured Obligations, whereupon the Security Agent discharged the Security (or any part thereof) expressed to be created pursuant to this Agreement, is avoided or reduced as a result of insolvency or any similar event:

- (a) the liability of the Pledgor and the Security granted under this Agreement shall, to the extent legally permitted, continue as if the payment, discharge, avoidance or reduction had not occurred and such amount shall not be considered to have been irrevocably paid and the liability of the Pledgor and the Security expressed to be created under this Agreement shall be reinstated and continue as if the payment, discharge, avoidance or reduction had not occurred; and
- (b) the Pledgor shall pledge, return and deliver (as the case may be) to the Security Agent any Pledged Asset, including, for the avoidance of doubt, any proceeds from the collection or disposal of and any other substitutes

for the Pledged Assets, as if the repayment, discharge, avoidance or reduction had not occurred.

13. Miscellaneous

13.1. Costs and expenses

All costs and expenses (including legal fees) arising out of or in connection with the preparation, execution, amendment and enforcement of, or any performance under, this Agreement shall be borne in accordance with the terms of the Facility Agreement.

13.2. Waivers and amendment

- (a) No failure on the part of the Security Agent or any other Pledgee to exercise, or delay on its part in exercising, any Collateral Right shall operate as a waiver thereof, nor shall any single or partial exercise of a Collateral Right preclude any further or other exercise of that or any other Collateral Right.
- (b) Any amendment or waiver of this Agreement or any provision of this Agreement (including this Clause 13.2 (*Waivers and amendment*)) shall only be binding if agreed in writing by all Parties.

13.3. Assignment or transfer

- (a) The Pledgor may not transfer or assign this Agreement or any rights or obligations hereunder without the prior written consent of the Security Agent.
- (b) If a successor of the Security Agent is appointed pursuant to the Finance Documents, the existing Security Agent may assign and transfer by way of written agreement all of its rights and obligations hereunder (including by way of transfer of agreement (*Vertragsübernahme/-übertragung*)) to its successor without further consent of the Pledgor. The Pledgor herewith irrevocably and unconditionally agrees in advance to such transfer and assignment and to recognise any such successor as

new Security Agent in substitution of the retiring Security Agent, and to do all acts (at its own cost) necessary or useful for the successor Security Agent to be recognised by third parties as new Security Agent hereunder (including countersigning the written agreement of assignment and transfer).

13.4. Notices

Any notice, request or other communication under this Agreement shall be given in accordance with the provisions of section 9.1 (*Notices*) of the Facility Agreement which shall apply to this Agreement *mutatis mutandis*.

13.5. Severability

If any provision of this Agreement is or becomes illegal, invalid or unenforceable in any jurisdiction, this shall not affect or impair (i) the validity or enforceability in that jurisdiction of any other provision of this Agreement or (ii) the validity or enforceability in any other jurisdiction of that or any other provision of this Agreement, and the Parties will negotiate in good faith to replace the relevant provision by another provision reflecting as closely as possible the original intention and purpose of the Parties.

13.6. Counterparts

This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

14. Law and jurisdiction

- (a) This Agreement shall in all respects, including, without limitation, all the rights in rem aspects, be governed by and construed in accordance with the substantive laws of Switzerland (to the exclusion of conflict of law rules).
- (b) Each Party submits to the exclusive jurisdiction of the courts of the city of Zurich, Switzerland (including a dispute regarding the existence, validity or termination of this Agreement or any non-contractual


obligation arising out of or in connection with this Agreement). The Security Agent and each other Pledgee reserves the right to bring an action against the Pledgor at its place of domicile or before any other competent court.

[SIGNATURE PAGE FOLLOWS]

Signatures

ADC THERAPEUTICS SA

Pledgor



Name: Chris Martin
Title: CEO

Name: Michael Forer
Title: Vice Chairman & EVP

DEERFIELD PARTNERS, L.P.

Security Agent

for itself and as direct representative (*direkter Stellvertreter*) in the name and for the account of the other Secured Parties

By: Deerfield Mgmt, L.P.,
its General Partner

By: J.E. Flynn Capital, LLC,
its General Partner

By: _____


Name: David J. Clark

Title: Authorized Signatory

Signatures

ADC THERAPEUTICS SA

Pledgor



Name: Chris Martin
Title: CEO

Name: Michael Forer
Title: Vice Chairman & EVP

DEERFIELD PARTNERS, L.P.

Security Agent

for itself and as direct representative (*direkter Stellvertreter*) in the name and for the account of the other Secured Parties

By: Deerfield Mgmt, L.P.,
its General Partner

By: J.E. Flynn Capital, LLC,
its General Partner

By: _____

Name: David J. Clark

Title: Authorized Signatory

Signatures

ADC THERAPEUTICS SA

Pledgor

Name:

Name:

Title:

Title:

DEERFIELD PARTNERS, L.P.


Security Agent

for itself and as direct representative (*direkter Stellvertreter*) in the name and for the account of the other Secured Parties

By: Deerfield Mgmt, L.P.,
its General Partner

By: J.E. Flynn Capital, LLC,
its General Partner

By:



Name: David J. Clark

Title: Authorized Signatory

Schedule 1: Existing Intellectual Property

A. Copyrights

[None as of the date hereof.] Homburger to confirm

B. Patents

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 1 AU (SGNAT-101AU1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	2013328619	11/10/2013	2013328619	02/03/2017	Australia
Patent 1 BR (SGNAT-101BR1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Pending	BR1120150081738	11/10/2013			Brazil
Patent 1 CA (SGNAT-101CA1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	2887894	11/10/2013	2887894	29/10/2019	Canada
Patent 1 CN (SGNAT-101CN1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	201380065405.7	11/10/2013	ZL201380065405.7	05/03/2019	China
Patent 1 IN (SGNAT-101IN1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Pending	1069/MUMNP/2015	11/10/2013			India

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 1 JP (SGNAT-101JP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	2015-536162	11/10/2013	6270859	12/01/2018	Japan
Patent 1 MX (SGNAT-101MX1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	MX/A/2015/004416	11/10/2013	364326	23/04/2019	Mexico
Patent 1 NZ (SGNAT-101NZ1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	707486	11/10/2013	707486	04/01/2019	New Zealand
Patent 1 ZA (SGNAT-101ZA1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	2015/02437	11/10/2013	2015/02437	25/10/2017	South Africa
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	2906253	01/08/2018	European Patent
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013		01/08/2018	Albania

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	2906253	01/08/2018	Austria
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	2906253	01/08/2018	Belgium
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013		01/08/2018	Bulgaria
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	2906253	01/08/2018	Switzerland
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	CY1120916	01/08/2018	Cyprus (S)
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	2906253	01/08/2018	Czech Republic

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	602013041276.6	01/08/2018	Germany
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	2906253	01/08/2018	Denmark
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	2906253	01/08/2018	Estonia
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	2690067	01/08/2018	Spain
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	2906253	01/08/2018	Finland
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	2906253	01/08/2018	France

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	3097620	01/08/2018	Greece
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	P20181646	01/08/2018	Croatia
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	E041274	01/08/2018	Hungary
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	2906253	01/08/2018	Ireland
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	2906253	01/08/2018	Iceland
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	502018000033160	01/08/2018	Italy

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	2906253	01/08/2018	Lithuania
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	2906253	01/08/2018	Luxembourg
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	2906253	01/08/2018	Latvia
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	2906253	01/08/2018	Monaco
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	2906253	01/08/2018	North Macedonia
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	2906253	01/08/2018	Malta

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	2906253	01/08/2018	Netherlands
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	2906253	01/08/2018	Norway
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	2906253	01/08/2018	Poland
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	2906253	01/08/2018	Portugal
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	2906253	01/08/2018	Romania
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	57694	01/08/2018	Serbia

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	2906253	01/08/2018	Sweden
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	2906253	01/08/2018	Slovenia
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	29021	01/08/2018	Slovak Republic
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	2906253	01/08/2018	San Marino
Patent 1 EP (SGNAT-101EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13795435.0	11/10/2013	TR201815418T4	01/08/2018	Turkey
Patent 2 EP (SGNAT-102EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	13785372.7	11/10/2013	2906250	30/05/2018	European Patent

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 2 EP (SGNAT-102EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES	Granted	13785372.7	11/10/2013	2906250	30/05/2018	Switzerland
Patent 2 EP (SGNAT-102EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES	Granted	13785372.7	11/10/2013	602013038266.2	30/05/2018	Germany
Patent 2 EP (SGNAT-102EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES	Granted	13785372.7	11/10/2013	2680153	30/05/2018	Spain
Patent 2 EP (SGNAT-102EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES	Granted	13785372.7	11/10/2013	2906250	30/05/2018	France
Patent 2 EP (SGNAT-102EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES	Granted	13785372.7	11/10/2013	2906250	30/05/2018	Ireland
Patent 2 EP (SGNAT-102EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES	Granted	13785372.7	11/10/2013	502018000025660	30/05/2018	Italy

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 2 EP (SGNAT-102EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES	Granted	13785372.7	11/10/2013	2906250	30/05/2018	Netherlands
Patent 4 AU (SGNAT-104AU1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	2013328623	11/10/2013	2013328623	30/03/2017	Australia
Patent 4 BR (SGNAT-104BR1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	BR 1120150081746	11/10/2013			Brazil
Patent 4 CA (SGNAT-104CA1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	2887895	11/10/2013	2887895	29/10/2019	Canada
Patent 4 CN (SGNAT-104CN1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	201380065424.X	11/10/2013	ZL201380065424.X	30/03/2018	China
Patent 4 IN (SGNAT-104IN1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	1090/MUMNP/2015	11/10/2013			India

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 4 JP (SGNAT-104JP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	2015-536164	11/10/2013	6392763	31/08/2018	Japan
Patent 4 MX (SGNAT-104MX1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	MX/A/2015/004449	11/10/2013	364329	23/04/2019	Mexico
Patent 4 NZ (SGNAT-104NZ1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	707534	11/10/2013	707534	04/12/2018	New Zealand
Patent 4 ZA (SGNAT-104ZA1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	2015/02428	11/10/2013	2015/02428	25/10/2017	South Africa
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	2906298	03/10/2018	European Patent
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	843	03/10/2018	Albania

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	2906298	03/10/2018	Austria
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	2906298	03/10/2018	Belgium
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013		03/10/2018	Bulgaria
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	2906298	03/10/2018	Switzerland
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	CY1121349	03/10/2018	Cyprus (S)
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	2906298	03/10/2018	Czech Republic

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	602013044545.1	03/10/2018	Germany
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	2906298	03/10/2018	Denmark
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	2906298	03/10/2018	Estonia
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	2703151	03/10/2018	Spain
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	2906298	03/10/2018	Finland
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	2906298	03/10/2018	France

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	3098343	03/10/2018	Greece
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	P20182129	03/10/2018	Croatia
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	E042731	03/10/2018	Hungary
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	2906298	03/10/2018	Ireland
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	2906298	03/10/2018	Iceland
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	502019000000922	03/10/2018	Italy

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	2906298	03/10/2018	Lithuania
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	2906298	03/10/2018	Luxembourg
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	2906298	03/10/2018	Latvia
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	2906298	03/10/2018	Monaco
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	2906298	03/10/2018	North Macedonia
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	2906298	03/10/2018	Malta

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	2906298	03/10/2018	Netherlands
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	2906298	03/10/2018	Norway
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	2906298	03/10/2018	Poland
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	2906298	03/10/2018	Portugal
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	2906298	03/10/2018	Romania
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	57964	03/10/2018	Serbia

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	2906298	03/10/2018	Sweden
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	2906298	03/10/2018	Slovenia
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	E 29638	03/10/2018	Slovak Republic
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	2906298	03/10/2018	San Marino
Patent 4 EP (SGNAT-104EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785831.2	11/10/2013	Tv 2018 18821 T4	03/10/2018	Turkey
Patent 6 AU (SGNAT-106AU1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	2013328625	11/10/2013	2013328625	30/03/2017	Australia

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 6 BR (SGNAT-106BR1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	BR1120150082327	11/10/2013			Brazil
Patent 6 CA (SGNAT-106CA1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	2887897	11/10/2013	2887897	18/02/2020	Canada
Patent 6 CN (SGNAT-106CN1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	201380065423.5	11/10/2013	ZL201380065423.5	01/06/2018	China
Patent 6 IN (SGNAT-106IN1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	1094/MUMNP/2015	11/10/2013			India
Patent 6 JP (SGNAT-106JP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	2015-536165	11/10/2013	6392764	31/08/2018	Japan
Patent 6 MX (SGNAT-106MX1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	MX/A/2015/004421	11/10/2013	364328	23/04/2019	Mexico

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 6 NZ (SGNAT-106NZ1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	707543	11/10/2013	707543	04/01/2019	New Zealand
Patent 6 ZA (SGNAT-106ZA1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	2015/02523	11/10/2013	2015/02523	27/09/2017	South Africa
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	2906296	21/03/2018	European Patent
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	7628	21/03/2018	Albania
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	2906296	21/03/2018	Austria
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	2906296	21/03/2018	Belgium

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013		21/03/2018	Bulgaria
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	2906296	21/03/2018	Switzerland
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	CY1120327	21/03/2018	Cyprus (S)
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	2906296	21/03/2018	Czech Republic
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	602013034757.3	21/03/2018	Germany
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	2906296	21/03/2018	Denmark

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	2906296	21/03/2018	Estonia
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	2670937	21/03/2018	Spain
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	2906296	21/03/2018	Finland
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	2906296	21/03/2018	France
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	3096098	21/03/2018	Greece
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	P20180945	21/03/2018	Croatia

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	E039329	21/03/2018	Hungary
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	2906296	21/03/2018	Ireland
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	2906296	21/03/2018	Iceland
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	5020180000017531	21/03/2018	Italy
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	2906296	21/03/2018	Lithuania
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	2906296	21/03/2018	Luxembourg

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	2906296	21/03/2018	Latvia
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	2906296	21/03/2018	Monaco
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013		21/03/2018	North Macedonia
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	2906296	21/03/2018	Malta
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	2906296	21/03/2018	Netherlands
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	2906296	21/03/2018	Norway

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	2906296	21/03/2018	Poland
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	2906296	21/03/2018	Portugal
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	2906296	21/03/2018	Romania
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	57104	21/03/2018	Serbia
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	2906296	21/03/2018	Sweden
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	2906296	21/03/2018	Slovenia

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	27632	21/03/2018	Slovak Republic
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	2906296	21/03/2018	San Marino
Patent 6 EP (SGNAT-106EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785373.5	11/10/2013	TR201808051T4	21/03/2018	Turkey
Patent 7 EP (SGNAT-107EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785374.3	11/10/2013	2906297	06/12/2017	European Patent
Patent 7 EP (SGNAT-107EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785374.3	11/10/2013	2906297	06/12/2017	Switzerland
Patent 7 EP (SGNAT-107EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785374.3	11/10/2013	602013030499.8	06/12/2017	Germany

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 7 EP (SGNAT-107EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785374.3	11/10/2013	2660029	06/12/2017	Spain
Patent 7 EP (SGNAT-107EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785374.3	11/10/2013	2906297	06/12/2017	France
Patent 7 EP (SGNAT-107EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785374.3	11/10/2013	2906297	06/12/2017	Ireland
Patent 7 EP (SGNAT-107EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785374.3	11/10/2013	502018000007476	06/12/2017	Italy
Patent 7 EP (SGNAT-107EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	13785374.3	11/10/2013	2906297	06/12/2017	Netherlands
Patent 9 AU (SGNAT-109AU1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	2013328628	11/10/2013	2013328628	30/03/2017	Australia

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 9 BR (SGNAT-109BR1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Pending	BR1120150082386	11/10/2013			Brazil
Patent 9 CA (SGNAT-109CA1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	2887899	11/10/2013	2887899	31/03/2020	Canada
Patent 9 CN (SGNAT-109CN1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	201380065412.7	11/10/2013	ZL201380065412.7	25/01/2019	China
Patent 9 IN (SGNAT-109IN1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Pending	1115/MUMNP/2015	11/10/2013			India
Patent 9 JP (SGNAT-109JP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	2015-536166	11/10/2013	6392765	31/08/2018	Japan
Patent 9 MX (SGNAT-109MX1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	MX/A/2015/004420	11/10/2013	364327	23/04/2019	Mexico

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 9 NZ (SGNAT-109NZ1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	707490	11/10/2013	707490	04/01/2019	New Zealand
Patent 9 ZA (SGNAT-109ZA1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	2015/02524	11/10/2013	2015/02524	30/05/2018	South Africa
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	2906251	27/09/2017	European Patent
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	7082	27/09/2017	Albania
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	2906251	27/09/2017	Austria
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	2906251	27/09/2017	Belgium

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013		27/09/2017	Bulgaria
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	2906251	27/09/2017	Switzerland
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	CY1119782	27/09/2017	Cyprus (S)
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	2906251	27/09/2017	Czech Republic
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	602013027209.3	27/09/2017	Germany
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	2906251	27/09/2017	Denmark

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	2906251	27/09/2017	Estonia
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	2649990	27/09/2017	Spain
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	2906251	27/09/2017	Finland
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	2906251	27/09/2017	France
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	3094563	27/09/2017	Greece
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	P20171916	27/09/2017	Croatia

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	E035694	27/09/2017	Hungary
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	2906251	27/09/2017	Ireland
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	2906251	27/09/2017	Iceland
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	502017000149754	27/09/2017	Italy
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	2906251	27/09/2017	Lithuania
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	2906251	27/09/2017	Luxembourg

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	2906251	27/09/2017	Latvia
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	2906251	27/09/2017	Monaco
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013			North Macedonia
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	2906251	27/09/2017	Malta
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013			Netherlands
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	2906251	27/09/2017	Norway

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	2906251	27/09/2017	Poland
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	2906251	27/09/2017	Portugal
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	2906251	27/09/2017	Romania
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	56520	27/09/2017	Serbia
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	2906251	27/09/2017	Sweden
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	2906251	27/09/2017	Slovenia

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	E26100T3	27/09/2017	Slovak Republic
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	2906251	27/09/2017	San Marino
Patent 9 EP (SGNAT-109EP1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	13786186.0	11/10/2013	TR201720163T4	27/09/2017	Turkey
Patent 13 EP (SGNAT-113EP1)	MedImmune Limited	ADC Therapeutics SA	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	14787022.4	10/10/2014	3054983	20/03/2019	European Patent
Patent 13 EP (SGNAT-113EP1)	MedImmune Limited	ADC Therapeutics SA	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	14787022.4	10/10/2014	3054983	20/03/2019	Switzerland
Patent 13 EP (SGNAT-113EP1)	MedImmune Limited	ADC Therapeutics SA	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	14787022.4	10/10/2014	602014043311.1	20/03/2019	Germany

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 13 EP (SGNAT-113EP1)	MedImmune Limited	ADC Therapeutics SA	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	14787022.4	10/10/2014	3054983	20/03/2019	France
Patent 13 EP (SGNAT-113EP1)	MedImmune Limited	ADC Therapeutics SA	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	14787022.4	10/10/2014	3054983	20/03/2019	Ireland
Patent 13 EP (SGNAT-113EP1)	MedImmune Limited	ADC Therapeutics SA	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	14787022.4	10/10/2014	3054983	20/03/2019	Netherlands
Patent 15 EP (SGNAT-115EP1)	MedImmune Limited	ADC Therapeutics SA	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	14787024.0	10/10/2014	3054985	26/12/2018	European Patent
Patent 15 EP (SGNAT-115EP1)	MedImmune Limited	ADC Therapeutics SA	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	14787024.0	10/10/2014	3054985	26/12/2018	Switzerland
Patent 15 EP (SGNAT-115EP1)	MedImmune Limited	ADC Therapeutics SA	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	14787024.0	10/10/2014	602014038719.5	26/12/2018	Germany

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 15 EP (SGNAT-115EP1)	MedImmune Limited	ADC Therapeutics SA	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	14787024.0	10/10/2014	3054985	26/12/2018	France
Patent 15 EP (SGNAT-115EP1)	MedImmune Limited	ADC Therapeutics SA	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	14787024.0	10/10/2014	3054985	26/12/2018	Ireland
Patent 15 EP (SGNAT-115EP1)	MedImmune Limited	ADC Therapeutics SA	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	14787024.0	10/10/2014	3054985	26/12/2018	Netherlands
Patent 17 EP (SGNAT-117EP1)	MedImmune Limited	ADC Therapeutics SA	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	14787025.7	10/10/2014	3054986	20/03/2019	European Patent
Patent 17 EP (SGNAT-117EP1)	MedImmune Limited	ADC Therapeutics SA	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	14787025.7	10/10/2014	3054986	20/03/2019	Switzerland
Patent 17 EP (SGNAT-117EP1)	MedImmune Limited	ADC Therapeutics SA	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	14787025.7	10/10/2014	602015043313.8	20/03/2019	Germany

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 17 EP (SGNAT-117EP1)	MedImmune Limited	ADC Therapeutics SA	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	14787025.7	10/10/2014	3054986	20/03/2019	France
Patent 17 EP (SGNAT-117EP1)	MedImmune Limited	ADC Therapeutics SA	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	14787025.7	10/10/2014	3054986	20/03/2019	Ireland
Patent 17 EP (SGNAT-117EP1)	MedImmune Limited	ADC Therapeutics SA	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	14787025.7	10/10/2014	3054986	20/03/2019	Netherlands
Patent 25 EP (SGNAT-125WO1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	15801398.7	25/11/2015			European Patent
Patent 25 WO (SGNAT-125WO1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	15/529622	25/11/2015			United States of America
Patent 25 WO (SGNAT-125WO1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	2015352545	25/11/2015			Australia

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 25 WO (SGNAT-125WO1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	BR112017011110	25/11/2015			Brazil
Patent 25 WO (SGNAT-125WO1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	2968447	25/11/2015			Canada
Patent 25 CN (SGNAT-125CN1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	20158072448.7	25/11/2015			China
Patent 25 WO (SGNAT-125WO1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	201727016706	25/11/2015			India
Patent 25 WO (SGNAT-125WO1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	2017-546038	25/11/2015			Japan

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 25 WO (SGNAT-125WO1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	10-2017-7014301	25/11/2015			South Korea
Patent 25 WO (SGNAT-125WO1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	MX/A/2017/006770	25/11/2015			Mexico
Patent 25 WO (SGNAT-125WO1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	731782	25/11/2015			New Zealand
Patent 25 ZA (SGNAT-125WO1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	2017/04297	25/11/2015			South Africa
Patent 26 EP (SGNAT-126WO1)	ADC Therapeutics SA	MedImmune Limited	DIAGNOSTIC TEST INVOLVING ANTI-CD25-ADC	Pending	15802044.6	25/11/2015			European Patent
Patent 26 US	ADC	MedImmune	DIAGNOSTIC TEST INVOLVING	Pending	15/571969	25/11/2015			United States of

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
(SGNAT-126WO1)	Therapeutics SA	Limited	ANTI-CD25-ADC						America
Patent 45 EP (SGNAT-145WO1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	15802045.3	25/11/2015			European Patent
Patent 45 US conf (SGNAT-145US2)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	16806910	25/11/2015			United States of America
Patent 55 EP (SGAT-155EP-1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	18704956.4	08/02/2018			European Patent
Patent 55 AU (SGAT-155AU-1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	2018217926	08/02/2018	2018217926	16/01/2020	Australia
Patent 55 BR (SGAT-155BR-1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	BR112019016373.5	08/02/2018			Brazil
Patent 55 CA	ADC	MedImmune	PYRROLOBENZODIAZEPINE-	Granted	3047683	08/02/2018	3047683	10/03/2020	Canada

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
(SGAT-155CA1)	Therapeutics SA	Limited	ANTIBODY CONJUGATES						
Patent 55 CN (SGAT-155CN-1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	201880010619.7	08/02/2018			China
Patent 55 IN (SGAT-155IN-1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	201927032948	08/02/2018			India
Patent 55 JP (SGAT-155JP-1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	2019-542659	08/02/2018			Japan
Patent 55 KR (SGAT-155KR-1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	10-2019-7023785	08/02/2018			South Korea
Patent 55 MX (SGAT-155MX-1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	MX/a/7019/009428	08/02/2018			Mexico
Patent 55 NZ (SGAT-155NZ-1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	754810	08/02/2018			New Zealand

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
155NZ-1)	SA								
Patent 55 ZA (SGAT-155ZA-1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	2019/04353	08/02/2018			South Africa
Patent 55 HK (SGAT-155HK-1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	62020002499.5	08/02/2018			Hong Kong
Patent 56 - 63 & 103 EP	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY	Pending	18721976.1	20/04/2018			European Patent
Patent 56 - 63 & 103 US	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY	Pending	16/605701	20/04/2018			United States of America
Patent 56 - 63 & 103 AU	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY	Pending	2018253951	20/04/2018			Australia
Patent 56 - 63 & 103 BR	ADC Therapeutics	MedImmune Limited	COMBINATION THERAPY	Pending	BR1120190218220	20/04/2018			Brazil

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
	SA								
Patent 56 - 63 & 103 CA	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY	Pending	3057749	20/04/2018			Canada
Patent 56 - 63 & 103 CN	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY	Pending	201880038974.5	20/04/2018			China
Patent 56 - 63 & 103 IN	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY	Pending	201927036586	20/04/2018			India
Patent 56 - 63 & 103 JP	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY	Pending	2019-556889	20/04/2018			Japan
Patent 56 - 63 & 103 MX	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY	Pending	MX/A/2019/012462	20/04/2018			Mexico
Patent 56 - 63 & 103 NZ	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY	Pending	756733	20/04/2018			New Zealand

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 56 - 63 & 103 ZA	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY	Pending	2019/05719	20/04/2018			South Africa
Patent 56 - 63 & 103 KR	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY	Pending	10-2019-7033821	20/04/2018			South Korea
Patent 64 - 71 EP	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY WITH AN ANTI-CD25 ANTIBODY- DRUG CONJUGATE	Pending	18719542.5	20/04/2018			European Patent
Patent 64 - 71 US	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY WITH AN ANTI-CD25 ANTIBODY- DRUG CONJUGATE	Pending	16/605708	20/04/2018			United States of America
Patent 64 - 71 AU	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY WITH AN ANTI-CD25 ANTIBODY- DRUG CONJUGATE	Pending	2018253950	20/04/2018			Australia
Patent 64 - 71 BR	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY WITH AN ANTI-CD25 ANTIBODY- DRUG CONJUGATE	Pending	BR1120190216804	20/04/2018			Brazil

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 64 - 71 CA	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY WITH AN ANTI-CD25 ANTIBODY- DRUG CONJUGATE	Pending	3057744	20/04/2018			Canada
Patent 64 - 71 CN	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY WITH AN ANTI-CD25 ANTIBODY- DRUG CONJUGATE	Pending	201880029617.2	20/04/2018			China
Patent 64 - 71 IN	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY WITH AN ANTI-CD25 ANTIBODY- DRUG CONJUGATE	Pending	201927036583	20/04/2018			India
Patent 64 - 71 JP	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY WITH AN ANTI-CD25 ANTIBODY- DRUG CONJUGATE	Pending	2019-556813	20/04/2018			Japan
Patent 64 - 71 MX	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY WITH AN ANTI-CD25 ANTIBODY- DRUG CONJUGATE	Pending	MX/A/2019/012465	20/04/2018			Mexico
Patent 64 - 71 NZ	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY WITH AN ANTI-CD25 ANTIBODY- DRUG CONJUGATE	Pending	756731	20/04/2018			New Zealand

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 64 - 71 ZA	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY WITH AN ANTI-CD25 ANTIBODY-DRUG CONJUGATE	Pending	2019/05728	20/04/2018			South Africa
Patent 64 - 71 KR	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY WITH AN ANTI-CD25 ANTIBODY-DRUG CONJUGATE	Pending	10-2019-7032525	20/04/2018			South Korea
Patent 80 - 86 EP	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY WITH AN ANTI-PSMA ANTIBODY-DRUG CONJUGATE	Pending	18719163.0	20/04/2018			European Patent
Patent 80 - 86 US	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY WITH AN ANTI-PSMA ANTIBODY-DRUG CONJUGATE	Pending	16/605710	20/04/2018			United States of America
Patent 87-95 US[bypass]	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE	Granted	16/197891	20/04/2018	10544223	28/01/2020	United States of America
Patent 87 - 95 EP	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE	Pending	18719162.2	20/04/2018			European Patent

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 87 - 95 US	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE	Pending	16/605692	20/04/2018			United States of America
Patent 87 - 95 AU	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE	Pending	2018253948	20/04/2018			Australia
Patent 87 - 95 BR	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE	Pending	BR 1120190218807	20/04/2018			Brazil
Patent 87 - 95 CA	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE	Pending	3057748	20/04/2018			Canada
Patent 87 - 95 CN	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE	Pending	201880025195.1	20/04/2018			China
Patent 87 - 95 IN	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE	Pending	201927036584	20/04/2018			India

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 87 - 95 JP	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE	Pending	2019-556986	20/04/2018			Japan
Patent 87 - 95 MX	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE	Pending	MX/A/2019/012464	20/04/2018			Mexico
Patent 87 - 95 NZ	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE	Pending	756730	20/04/2018			New Zealand
Patent 87 - 95 ZA	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE	Pending	2019/05727	20/04/2018			South Africa
Patent 87 - 95 KR	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY WITH AN ANTI-AXL ANTIBODY-DRUG CONJUGATE	Pending	10-2019-7030286	20/04/2018			South Korea
Patent 96 & 99 EP	ADC Therapeutics SA	MedImmune Limited	DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD25 ADC	Pending	18732040.3	14/06/2018			European Patent

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 96 & 99 US	ADC Therapeutics SA	MedImmune Limited	DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD25 ADC	Pending	16/622663	14/06/2018			United States of America
Patent 96 & 99 AU	ADC Therapeutics SA	MedImmune Limited	DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD25 ADC	Pending	2018285455	14/06/2018			Australia
Patent 96 & 99 BR	ADC Therapeutics SA	MedImmune Limited	DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD25 ADC	Pending	BR 1120190264981	14/06/2018			Brazil
Patent 96 & 99 CA	ADC Therapeutics SA	MedImmune Limited	DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD25 ADC	Pending	3064681	14/06/2018			Canada
Patent 96 & 99 JP	ADC Therapeutics SA	MedImmune Limited	DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD25 ADC	Pending	2019-569364	14/06/2018			Japan
Patent 96 & 99 MX	ADC Therapeutics SA	MedImmune Limited	DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD25 ADC	Pending	MX/a/2019/014923	14/06/2018			Mexico

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 96 & 99 NZ	ADC Therapeutics SA	MedImmune Limited	DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD25 ADC	Pending	759150	14/06/2018			New Zealand
Patent 96 & 99 ZA	ADC Therapeutics SA	MedImmune Limited	DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD25 ADC	Pending	2019/07611	14/06/2018			South Africa
Patent 96 & 99 KR	ADC Therapeutics SA	MedImmune Limited	DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD25 ADC	Pending	10-2020-7001219	14/06/2018			South Korea
Patents 97 & 98 EP	ADC Therapeutics SA	MedImmune Limited	DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD19 ADC	Pending	18732041.1	14/06/2018			European Patent
Patents 97 & 98 US	ADC Therapeutics SA	MedImmune Limited	DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD19 ADC	Pending	16/622649	14/06/2018			United States of America
Patents 97 & 98 AU	ADC Therapeutics SA	MedImmune Limited	DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD19 ADC	Pending	2018285562	14/06/2018			Australia

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patents 97 & 98 BR	ADC Therapeutics SA	MedImmune Limited	DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD19 ADC	Pending	BR1120190265643	14/06/2018			Brazil
Patents 97 & 98 CA	ADC Therapeutics SA	MedImmune Limited	DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD19 ADC	Pending	3064804	14/06/2018			Canada
Patents 97 & 98 JP	ADC Therapeutics SA	MedImmune Limited	DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD19 ADC	Pending	2019-569479	14/06/2018			Japan
Patents 97 & 98 MX	ADC Therapeutics SA	MedImmune Limited	DOSAGE REGIME FOR THE ADMINISTRATION OF AN ANTI-CD ADC	Pending	MX/a/2019/015042	14/06/2018			Mexico
Patents 97 & 98 NZ	ADC Therapeutics SA	MedImmune Limited	DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD19 ADC	Pending	759283	14/06/2018			New Zealand
Patents 97 & 98 ZA	ADC Therapeutics SA	MedImmune Limited	DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD19 ADC	Pending	2019/07613	14/06/2018			South Africa

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patents 97 & 98 KR	ADC Therapeutics SA	MedImmune Limited	DOSAGE REGIMES FOR THE ADMINISTRATION OF AN ANTI-CD19 ADC	Pending	10-2019-7037482	14/06/2018			South Korea
Patent 102/104/105 EP (SGAT-1102WO-1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	18706437.3	08/02/2018			European Patent
Patent 102/104/105 US (SGAT-1102WO-1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	16484313	08/02/2018			United States of America
Patent 102/104/105 AU (SGAT-1102WO-1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	2018219654	08/02/2018	2018219654	23/01/2020	Australia
Patent 102/104/105 BR (SGAT-1102WO-1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	BR1120190164200	08/02/2018			Brazil

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 102/104/105 CA (SGAT- 1102WO-1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES	Pending	3047686	08/02/2018			Canada
Patent 102/104/105 CN (SGAT- 1102WO-1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES	Pending	201880009386.9	08/02/2018			China
Patent 102/104/105 IN (SGAT- 1102WO-1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES	Pending	201927032945	08/02/2018			India
Patent 102/104/105 JP (SGAT- 1102WO-1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES	Pending	2019-542213	08/02/2018			Japan
Patent 102/104/105 KR (SGAT- 1102WO-1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES	Pending	10-2019-7023786	08/02/2018			South Korea

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 102/104/105 MX (SGAT- 1102WO-1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES	Pending	MX/a/2019/009427	08/02/2018			Mexico
Patent 102/104/105 NZ (SGAT- 1102WO-1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES	Pending	754811	08/02/2018			New Zealand
Patent 102/104/105 ZA (SGAT- 1102WO-1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES	Pending	2019/04269	08/02/2018			South Africa
Patent 102/104/105	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE- ANTIBODY CONJUGATES	Pending	62020002383.1	08/02/2018			Hong Kong
11504-035	ADC Therapeutics SA		POLYNUCLEOTIDES AND POLYPEPTIDE SEQUENCES INVOLVED IN CANCER	Issued	2007262635	6/22/2017	2007262635	1/8/2015	Australia
11504-036	ADC		POLYNUCLEOTIDES AND	Issued	2,655,933	6/22/2017	2655933	9/9/2014	Canada

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
	Therapeutics SA		POLYPEPTIDE SEQUENCES INVOLVED IN CANCER						
11504-037	ADC Therapeutics SA		POLYNUCLEOTIDES AND POLYPEPTIDE SEQUENCES INVOLVED IN CANCER	Issued	07720048.3	6/22/2017	2032701	11/27/2013	European Patent Office
11504-038	ADC Therapeutics SA		POLYNUCLEOTIDES AND POLYPEPTIDE SEQUENCES INVOLVED IN CANCER	Issued	2009-515683	6/22/2017	5564249	6/20/2014	Japan
11504-039	ADC Therapeutics SA		POLYNUCLEOTIDES AND POLYPEPTIDE SEQUENCES INVOLVED IN CANCER	Issued	12/305,648	6/22/2017	8216582	7/10/2012	United States of America
11504-126	ADC Therapeutics SA		POLYNUCLEOTIDES AND POLYPEPTIDE SEQUENCES INVOLVED IN CANCER	Issued	12163634.4	6/22/2017	2502628	12/14/2016	European Patent Office
11504-159	ADC Therapeutics SA		POLYNUCLEOTIDES AND POLYPEPTIDE SEQUENCES INVOLVED IN CANCER	Issued	2014-24778	6/22/2017	5589149	8/1/2014	Japan
11504-240	ADC Therapeutics		POLYNUCLEOTIDES AND POLYPEPTIDE SEQUENCES	Issued	16203468.0	6/22/2017	3231442	12/25/2019	European Patent Office

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
	SA		INVOLVED IN CANCER						
11504-247	ADC Therapeutics SA		POLYNUCLEOTIDES AND POLYPEPTIDE SEQUENCES INVOLVED IN CANCER	Pending	17112476.9	6/22/2017			Hong Kong
11504-251	ADC Therapeutics SA		POLYNUCLEOTIDES AND POLYPEPTIDE SEQUENCES INVOLVED IN CANCER	Pending	15/863,594	6/22/2017			United States of America
11504-074	ADC Therapeutics SA		ANTIBODIES THAT SPECIFICALLY BLOCK THE BIOLOGICAL ACTIVITY OF A TUMOR ANTIGEN	Issued	2,740,900	11/3/2009	2740900	9/24/2019	Canada
11504-075	ADC Therapeutics SA		ANTIBODIES THAT SPECIFICALLY BLOCK THE BIOLOGICAL ACTIVITY OF A TUMOR ANTIGEN	Issued	13/127,439	11/3/2009	9855291	2/2/2018	United States of America
11504-077	ADC Therapeutics SA		ANTIBODIES THAT SPECIFICALLY BLOCK THE BIOLOGICAL ACTIVITY OF A TUMOR ANTIGEN	Issued	2011-533500	11/3/2009	5781932	7/24/2015	Japan

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
11504-078	ADC Therapeutics SA		ANTIBODIES THAT SPECIFICALLY BLOCK THE BIOLOGICAL ACTIVITY OF A TUMOR ANTIGEN	Issued	2009321508	11/3/2009	2009321508	6/25/2015	Australia
11504-079	ADC Therapeutics SA		ANTIBODIES THAT SPECIFICALLY BLOCK THE BIOLOGICAL ACTIVITY OF A TUMOR ANTIGEN	Issued	200980143778.5	11/3/2009	ZL200980143778.5	8/27/2014	China
11504-082	ADC Therapeutics SA		ANTIBODIES THAT SPECIFICALLY BLOCK THE BIOLOGICAL ACTIVITY OF A TUMOR ANTIGEN	Issued	Mx/a/2011/0046684	11/3/2009	336869	2/4/2016	Mexico
11504-084	ADC Therapeutics SA		ANTIBODIES THAT SPECIFICALLY BLOCK THE BIOLOGICAL ACTIVITY OF A TUMOR ANTIGEN	Issued	592432	11/3/2009	592432	4/30/2013	New Zealand
11504-090	ADC Therapeutics SA		ANTIBODIES THAT SPECIFICALLY BLOCK THE BIOLOGICAL ACTIVITY OF A TUMOR ANTIGEN	Issued	13/187,424	11/3/2009	8580257	11/12/2013	United States of America

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
11504-233	ADC Therapeutics SA		ANTIBODIES THAT SPECIFICALLY BLOCK THE BIOLOGICAL ACTIVITY OF A TUMOR ANTIGEN	Pending	16171408.4	11/3/2009			European Patent Office
11504-242	ADC Therapeutics SA		ANTIBODIES THAT SPECIFICALLY BLOCK THE BIOLOGICAL ACTIVITY OF A TUMOR ANTIGEN	Pending	17108005.7	11/3/2009			Hong Kong
11504-248	ADC Therapeutics SA		ANTIBODIES THAT SPECIFICALLY BLOCK THE BIOLOGICAL ACTIVITY OF A TUMOR ANTIGEN	Pending	150833.753	11/3/2009			United States of America
11504-260	ADC Therapeutics SA		ANTIBODIES THAT SPECIFICALLY BLOCK THE BIOLOGICAL ACTIVITY OF A TUMOR ANTIGEN	Pending	3,050,455	11/3/2009			Canada
11504-144	ADC Therapeutics SA		ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Issued	2012234754		2012234754	1/12/2017	Australia

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
11504-145	ADC Therapeutics SA		ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Pending	BR112013025193-0	3/28/2012			Brazil
11504-146	ADC Therapeutics SA		ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Issued	2,829,105	3/28/2012	2829105	9/24/2019	Canada
11504-147	ADC Therapeutics SA		ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Issued	201280015597.6	3/28/2012	ZL20280015597.6	6/29/2016	China
11504-148	ADC Therapeutics SA		ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Pending	201391423	3/28/2012			Eurasian Patent Office
11504-149	ADC Therapeutics SA		ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Issued	12765926.6	3/28/2012	2691421	11/9/2016	European Patent Office

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
11504-150	ADC Therapeutics SA		ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Pending	3184/KOLNP/2013	3/28/2012			India
11504-151	ADC Therapeutics SA		ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Issued	228434	3/28/2012	228434	9/1/2018	Israel
11504-152	ADC Therapeutics SA		ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Issued	2014-501372	3/28/2012	6294221	2/23/2018	Japan
11504-153	ADC Therapeutics SA		ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Issued	Mx/a/2013/011354	3/28/2012	352373	11/22/2017	Mexico
11504-154	ADC Therapeutics SA		ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Issued	615694	3/28/2012	615694	5/1/2015	New Zealand

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
11504-155	ADC Therapeutics SA		ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Issued	10-2013-7026861	3/28/2012	10-1993259	6/20/2019	Republic of Korea
11504-156	ADC Therapeutics SA		ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Issued	2013/07027	3/28/2012	2013/07027	8/31/2016	South Africa
11504-157	ADC Therapeutics SA		ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Issued	14/036,204	3/28/2012	8937163	1/20/2015	United States of America
11504-189	ADC Therapeutics SA		ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Issued	14107223.8	3/28/2012	1193835	3/2/2018	Hong Kong
11504-215	ADC Therapeutics SA		ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Issued	14/558,186	3/28/2012	9393302	7/19/2016	United States of America

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
11504-218	ADC Therapeutics SA		ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Pending	2,888,908	3/28/2012			Canada
11504-224	ADC Therapeutics SA		ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Pending	2,893,376	3/28/2012			Canada
11504-231	ADC Therapeutics SA		ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Issued	15/137,368	3/28/2012	9828426	11/28/2017	United States of America
11504-236	ADC Therapeutics SA		ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Pending	201610534416.0	3/28/2012			China
11504-238	ADC Therapeutics SA		ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Issued	16190193.9	3/28/2012	3173427	6/19/2019	European Patent Office

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
11504-245	ADC Therapeutics SA		ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Issued	15/811,545	3/28/2012	10597450	3/24/2020	United States of America
11504-246	ADC Therapeutics SA		ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Issued	17112341.2	3/28/2012	1238268	2/7/2020	Hong Kong
11504-249	ADC Therapeutics SA		ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Pending	Mx/a/2017/014913	3/28/2012			Mexico
11504-250	ADC Therapeutics SA		ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Issued	2017-235147	3/28/2012	6650432	2/19/2020	Japan
11504-256	ADC Therapeutics SA		ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Pending	19155812.1	3/28/2012			European Patent Office

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
11504-258	ADC Therapeutics SA		ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Pending	266452	3/28/2012			Israel
11504-259	ADC Therapeutics SA		ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Allowed	10-2019-7017755	3/28/2012			Republic of Korea
11504-265	ADC Therapeutics SA		ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Pending	16707,482	3/28/2012			United States of America
11504-266	ADC Therapeutics SA		ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Pending	20001302.7	3/28/2012			Hong Kong
11504-268	ADC Therapeutics SA		ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF	Pending	2020-5907	3/28/2012			Japan

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
11504-163	ADC Therapeutics SA		METHOD FOR TREATING BREAST CANCER	Issued	2013209234	1/9/2013	2013209234	1/22/2018	Australia
11504-164	ADC Therapeutics SA		METHOD FOR TREATING BREAST CANCER	Pending	BR112014016723-0	1/9/2013			Brazil
11504-165	ADC Therapeutics SA		METHOD FOR TREATING BREAST CANCER	Pending	2,857,400	1/9/2013			Canada
11504-166	ADC Therapeutics SA		METHOD FOR TREATING BREAST CANCER	Issued	201380005017 X	1/9/2013	ZL201380005017 X	3/3/2020	China
11504-167	ADC Therapeutics SA		METHOD FOR TREATING BREAST CANCER	Issued	201491352	1/9/2013	034414	2/5/2020	Eurasian Patent Office
11504-168	ADC Therapeutics SA		METHOD FOR TREATING BREAST CANCER	Issued	13735811.5	1/9/2013	2802351	3/27/2019	European Patent Office

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
11504-171	ADC Therapeutics SA		METHOD FOR TREATING BREAST CANCER	Issued	2014-551488	1/9/2013	6282597	2/2/2018	Japan
11504-172	ADC Therapeutics SA		METHOD FOR TREATING BREAST CANCER	Issued	Mx/a/2014/008410	1/9/2013	366973	8/1/2019	Mexico
11504-173	ADC Therapeutics SA		METHOD FOR TREATING BREAST CANCER	Issued	625758	1/9/2013	625758	8/30/2016	New Zealand
11504-174	ADC Therapeutics SA		METHOD FOR TREATING BREAST CANCER	Issued	10-2014-7018877	1/9/2013	10-2102239	4/13/2020	Republic of Korea
11504-175	ADC Therapeutics SA		METHOD FOR TREATING BREAST CANCER	Pending	2014/04798	1/9/2013			South Africa
11504-222	ADC Therapeutics SA		METHOD FOR TREATING BREAST CANCER	Issued	15104275.1	1/9/2013	HK1203816	12/29/2019	Hong Kong

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
11504-243	ADC Therapeutics SA		METHOD FOR TREATING BREAST CANCER	Issued	254964	1/9/2013			Israel
11504-244	ADC Therapeutics SA		METHOD FOR TREATING BREAST CANCER	Issued	2017-213873	1/9/2013	6392435	8/31/2018	Japan
11504-254	ADC Therapeutics SA		METHOD FOR TREATING BREAST CANCER	Pending	16164,656	1/9/2013			United States of America
11504-255	ADC Therapeutics SA		METHOD FOR TREATING BREAST CANCER	Pending	19156516.7	1/9/2013			European Patent Office
11504-257	ADC Therapeutics SA		METHOD FOR TREATING BREAST CANCER	Pending	202010098137.0	1/9/2013			China
11504-261	ADC Therapeutics SA		METHOD FOR TREATING BREAST CANCER	Pending	MX/a/2019/009121	1/9/2013			Mexico

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
11504-262	ADC Therapeutics SA		METHOD FOR TREATING BREAST CANCER	Pending	201992513	1/9/2013			Eurasian Patent Office
11504-267	ADC Therapeutics SA		METHOD FOR TREATING BREAST CANCER	Pending	42020003175.5	1/9/2013			Hong Kong
007345390	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	15897835	2/15/18			United States
007346323	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	15911592	3/5/18			United States
007330178	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Pending	15884665	1/31/18			United States
007305261	ADC Therapeutics SA	MedImmune Limited	HUMANIZED ANTI-AXL ANTIBODIES AND THEIR CONJUGATES	Pending	15566639	10/13/17			United States

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
007112873	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	14434816	4/10/15	9931414	4/3/18	United States
007112030	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	14434823	4/10/15	9931415	4/3/18	United States
007112170	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	14434826	4/10/15	9919056	3/20/18	United States
Patent 1 KR (SGNAT-101KR1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE - ANTI-PSMA ANTIBODY CONJUGATES	Granted	10-2015-7012364	11/10/2013	10-1986404	30/05/2019	South Korea
Patent 4 KR (SGNAT-104KR1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Granted	10-2015-7012366	11/10/2013	10-1995619	26/06/2019	South Korea
Patent 9 KR (SGNAT-109KR1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTI-CD22 ANTIBODY CONJUGATES	Granted	10-2015-7012368	11/10/2013	10-1995671	26/06/2019	South Korea

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 28 US Cont (SGNAT-128WO1)	ADC Therapeutics SA	Medimmune Limited	SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES	Pending	16/731528	15/04/2015			United States of America
Patent 28 EP(SGNAT-128WO1)	ADC Therapeutics SA	Medimmune Limited	SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES	Pending	16716583.6	15/04/2016			European Patent
Patent 28 AU (SGNAT-128WO1)	ADC Therapeutics SA	Medimmune Limited	SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES	Pending	2016249877	15/04/2016			Australia
Patent 28 BR (SGNAT-128WO1)	ADC Therapeutics SA	Medimmune Limited	SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES	Pending	BR1120170222566	15/04/2016			Brazil
Patent 28 CA (SGNAT-128WO1)	ADC Therapeutics SA	Medimmune Limited	SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES	Pending	2981920	15/04/2015			Canada
Patent 28 CN (SGNAT-128WO1)	ADC Therapeutics SA	Medimmune Limited	SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES	Pending	201680022066.8	15/04/2016			China

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 28 IN (SGNAT-128WO1)	ADC Therapeutics SA	MedImmune Limited	SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES	Pending	201727039662	15/04/2016			India
Patent 28 JP (SGNAT-128WO1)	ADC Therapeutics SA	MedImmune Limited	SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES	Pending	2017-553879	15/04/2016			Japan
Patent 28 MX (SGNAT-128WO1)	ADC Therapeutics SA	MedImmune Limited	SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES	Pending	MX/A/2017/013154	15/04/2016			Mexico
Patent 28 NZ (SGNAT-128WO1)	ADC Therapeutics SA	MedImmune Limited	SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES	Pending	735885	15/04/2016			New Zealand
Patent 28 ZA (SGNAT-128WO1)	ADC Therapeutics SA	MedImmune Limited	SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES	Pending	2017/06704	15/04/2016			South Africa
Patent 28 KR (SGNAT-128WO1)	ADC Therapeutics SA	MedImmune Limited	SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES	Pending	10-2017-7030351	15/04/2016			South Korea

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 31 US Cont (SGNAT-131WO1)	ADC Therapeutics SA	MedImmune Limited	SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES	Pending	16/684222	15/04/2015			United States of America
Patent 31 WO (SGNAT-131WO1)	ADC Therapeutics SA	MedImmune Limited	SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES	Pending	16716589.3	15/04/2016			European Patent
Patent 31 AU (SGNAT-131WO1)	ADC Therapeutics SA	MedImmune Limited	SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES	Pending	2016247584	15/04/2016			Australia
Patent 31 BR (SGNAT-131WO1)	ADC Therapeutics SA	MedImmune Limited	SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES	Pending	BR1120170222582	15/04/2016			Brazil
Patent 31 CA (SGNAT-131WO1)	ADC Therapeutics SA	MedImmune Limited	SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES	Pending	2982522	15/04/2015			Canada
Patent 31 CN (SGNAT-131WO1)	ADC Therapeutics SA	MedImmune Limited	SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES	Pending	201680022088.4	15/04/2016			China

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 31 IN (SGNAT-131WO1)	ADC Therapeutics SA	MedImmune Limited	SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES	Pending	201727040436	15/04/2016			India
Patent 31 JP (SGNAT-131WO1)	ADC Therapeutics SA	MedImmune Limited	SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES	Pending	2017-554082	15/04/2016			Japan
Patent 31 MX (SGNAT-131WO1)	ADC Therapeutics SA	MedImmune Limited	SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES	Pending	MX/A/2017/013167	15/04/2016			Mexico
Patent 31 NZ (SGNAT-131WO1)	ADC Therapeutics SA	MedImmune Limited	SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES	Pending	736010	15/04/2016			New Zealand
Patent 31 ZA (SGNAT-131WO1)	ADC Therapeutics SA	MedImmune Limited	SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES	Pending	2017/06745	15/04/2016			South Africa
Patent 31 KR (SGNAT-131WO1)	ADC Therapeutics SA	MedImmune Limited	SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES	Pending	10-2017-7030358	15/04/2016			South Korea

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 55 US (SGAT-155US-1)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	16/484328	08/02/2018			United States of America
Patent 55 KRdiv (SGAT-155KR-2)	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES	Pending	10-2020-7007470	08/02/2018			South Korea
Patent 101 WO	ADC Therapeutics SA	MedImmune Limited	TREATMENT OF CAR T-CELL TOXICITY	Pending	PCT/EP2019/053165	08/02/2019			International
Patent 106 WO	ADC Therapeutics SA	MedImmune Limited	PYRROLOBENZODIAZEPINE RESISTANCE	Pending	PCT/EP2019/086079	18/12/2019			International
Patent 109 & 112 WO	ADC Therapeutics SA	MedImmune Limited	MOLECULAR ADJUVANT	Pending	PCT/EP2019/063262	22/05/2019			International
Patent 114 WO	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY	Pending	PCT/EP2019/068287	08/07/2019			International

IP Pledge Agreement

Internal Reference	1st Applicant	2nd Applicant	Title	Status	Application No.	Application Date	Granted Right No.	Grant Date	Jurisdiction
Patent 116 WO	ADC Therapeutics SA	MedImmune Limited	COMBINATION THERAPY	Pending	PCT/EP2019/073212	30/08/2019			International
Patent 118b USprov	ADC Therapeutics SA	MedImmune Limited	DOSAGE REGIME	Pending	62/883867	07/08/2019			United States of America
Patent 118 WO	ADC Therapeutics SA	MedImmune Limited	DOSAGE REGIME	Pending	PCT/EP2019/082464	25/11/2019			International

C. Trademarks

Trademark	Appl. Date	Reg. Date	Appl. No.	Reg. No.	Jurisdiction
ADC THERAPEUTICS (WORD MARK)	March 22, 2012	December 3, 2013	85577148	4445250	United States
ADC THERAPEUTICS (WORD MARK)	January 11, 2016	July 17, 2018	86983736	5516438	United States
ADC THERAPEUTICS (WORD MARK)	February 12, 2016	October 23, 2017	015101471	015101471	The European Union Trademark
ADC THERAPEUTICS (WORD MARK)	May 8, 2018		72974-2018		Switzerland
ADC THERAPEUTICS (WORD MARK)	May 8, 2018	December 10, 2018	201805966	301522	Norway
ADC THERAPEUTICS (WORD MARK)	May 8, 2018	August 2, 2019	2018059483	6168443	Japan
ADC THERAPEUTICS (WORD MARK)	May 9, 2018		1898283		Canada

Trademark	Appl. Date	Reg. Date	Appl. No.	Reg. No.	Jurisdiction
ADC THERAPEUTICS (WORD MARK)	May 8, 2018		2082057		Australia
ADC THERAPEUTICS LOGO	January 11, 2016	July 17, 2018	86983735	5516437	United States
ADC THERAPEUTICS LOGO	February 12, 2016	October 18, 2017	015103583	015103583	The European Union Trademark
ADC THERAPEUTICS LOGO	May 8, 2018		72975-2018		Switzerland
ADC THERAPEUTICS LOGO	May 8, 2018	December 10, 2018	201805965	301521	Norway
ADC THERAPEUTICS LOGO	May 8, 2018	November 9, 2018	1092480	1092480	New Zealand
ADC THERAPEUTICS LOGO	May 8, 2018	August 2, 2019	2018-059484	6168444	Japan
ADC THERAPEUTICS LOGO	May 9, 2018		1898284		Canada
ADC THERAPEUTICS	May 8, 2018		2082053		Australia

Trademark	Appl. Date	Reg. Date	Appl. No.	Reg. No.	Jurisdiction
LOGO					
ADCROZ	July 9, 2019		88506312		United States
ADCROZ	March 26, 2020		1512089		Ukraine
ADCROZ	January 7, 2020		1512089		Turkey
ADCROZ	January 7, 2020		1512089		The European Union Trademark
ADCROZ	January 7, 2020		1512089		Switzerland
ADCROZ	January 7, 2020		1512089		Singapore
ADCROZ	January 7, 2020		1512089		Russian Federation
ADCROZ	January 7, 2020		1512089		Republic of Korea
ADCROZ	January 7, 2020		1512089		Norway
ADCROZ	January 7, 2020		1512089		New Zealand
ADCROZ	January 7, 2020		1512089		Mexico
ADCROZ	January 7, 2020		1512089		Japan

Trademark	Appl. Date	Reg. Date	Appl. No.	Reg. No.	Jurisdiction
ADCROZ	January 7, 2020		1512089		Israel
ADCROZ	January 7, 2020	January 7, 2020	A0093087	1512089	International
ADCROZ	January 7, 2020		1512089		India
ADCROZ	January 7, 2020		1512089		Iceland
ADCROZ	January 7, 2020		1512089		China P.R.
ADCROZ	January 7, 2020		1512089		Canada
ADCROZ	January 7, 2020		1512089		Brazil
ADCROZ	January 7, 2020		1512089		Australia
ADCROZ	January 6, 2020		109000680		Taiwan
ADCROZ	January 6, 2020		305161923		Hong Kong
ADCT (WORD MARK)	January 11, 2016		86871990		United States
ADCT (WORD MARK)	February 12, 2016	June 10, 2016	015101553	015101553	The European Union Trademark
ADCT LOGO	February 13, 2018		87796629		United States

Trademark	Appl. Date	Reg. Date	Appl. No.	Reg. No.	Jurisdiction
CATCHLIGHT	October 21, 2019		88662016		United States
CATCHLIGHT LOGO	October 21, 2019		88662133		United States
ZYNLONTA	July 9, 2019		88506358		United States
ZYNLONTA	March 26, 2020		1512100		Ukraine
ZYNLONTA	January 7, 2020		1512100		Turkey
ZYNLONTA	January 7, 2020		1512100		The European Union Trademark
ZYNLONTA	January 6, 2020		109000679		Taiwan
ZYNLONTA	January 7, 2020		1512100		Switzerland
ZYNLONTA	January 7, 2020		1512100		Singapore
ZYNLONTA	January 7, 2020		1512100		Russian Federation
ZYNLONTA	January 7, 2020		1512100		Republic of Korea
ZYNLONTA	January 7, 2020		1512100		Norway
ZYNLONTA	January 7, 2020		1512100		New Zealand

Trademark	Appl. Date	Reg. Date	Appl. No.	Reg. No.	Jurisdiction
ZYNLONTA	January 7, 2020		1512100		Mexico
ZYNLONTA	January 7, 2020		1512100		Japan
ZYNLONTA	January 7, 2020		1512100		Israel
ZYNLONTA	January 7, 2020	January 7, 2020	A6093089	1512100	International
ZYNLONTA	January 7, 2020		1512100		India
ZYNLONTA	January 7, 2020		1512100		Iceland
ZYNLONTA	January 7, 2020		1512100		China P.R.
ZYNLONTA	January 7, 2020		1512100		Canada
ZYNLONTA	January 7, 2020		1512100		Brazil
ZYNLONTA	January 7, 2020		1512100		Australia
ZYNLONTA	January 6, 2020		305161996		Hong Kong
ADC THERAPEUTICS (WORD MARK)	April 28, 2020		327223		Israel

Trademark	Appl. Date	Reg. Date	Appl. No.	Reg. No.	Jurisdiction
ADC THERAPEUTICS (WORD MARK)	April 28, 2020		m202008007		Ukraine
ADC THERAPEUTICS LOGO	April 28, 2020		327225		Israel
ADC THERAPEUTICS LOGO	April 28, 2020		m202008009		Ukraine
ADCROZ	April 24, 2020		3889094		Argentina
ZYNLONTA	April 24, 2020		3889095		Argentina

D. Domain Names

adc-axl.com
adc-cd19.com
adc-cd22.com
adc-cd25.com
adc-her2.com
adc-muc1.com
adc-psma.com
adc-tx.com
adcenko.com
adcroz.com
adct-301.com
adct-401.com
adct-402.com
adct-501.com
adct-502.com
adct-601.com
adct-602.com
adct-701.com
adct-801.com
adct-901.com
adct-rd.com
adct301.com
adct401.com
adct402.com
adct501.com
adct502.com
adct601.com
adct602.com
adct701.com
adct801.com
adct901.com
adctbio.com
adctdev.com
ADCTHERAPEUTICS.COM
adcthr.com
adctrd.com

adctrx.com
adctsa.com
adloncare.com
adloncta.com
adlymca.com
aremyzta.com
cami-t.ch
cami-t.co.uk
cami-t.com
camidanlumab-tesirine.ch
camidanlumab-tesirine.co.uk
camidanlumab-tesirine.com
camidanlumab.ch
camidanlumab.co.uk
camidanlumab.com
camidanlumabtesirine.ch
camidanlumabtesirine.co.uk
camidanlumabtesirine.com
limfyxta.com
lonadca.com
lonca-b.ch
lonca-b.co.uk
lonca-b.com
lonca-t.ch
lonca-t.co.uk
lonca-t.com
lonca.ch
lonca.co.uk
loncab.ch
loncab.co.uk
loncadcaide.com
loncadceutix.com
loncafyte.com
loncastuximab-tesirine.ch
loncastuximab-tesirine.co.uk
loncastuximab-tesirine.com
loncastuximab.ch
loncastuximab.co.uk
loncastuximab.com
loncastuximabtesirine.ch
loncastuximabtesirine.co.uk

loncastuximabtesirine.com
loncat.ch
loncat.co.uk
loncattend.com
lontadca.com
synadca.com
THEADCCOMPANY.CO.UK
THEADCCOMPANY.COM
thxlp.com
viqtior.com
xixadca.com
xixvias.com
zoloncos.com
zynlonta.com

E. Others

N/A

Schedule 2a: Form of Notification Letter to the World Institute of Intellectual Property Organisation

Registered Mail

World Intellectual Property Organization
 34, chemin des Colombettes
 P.O. Box 18
 1211 Geneva 20
 Switzerland

[Place, date]

Pledge of Trademarks

Dear Sirs

We hereby inform you that we entered into a pledge agreement dated [...] (the **Agreement**, enclosed herewith) based on which we have pledged to [*Name and Address of the Security Agent*] (the **Security Agent**) the following trademarks, i.e.:

[...]

The Security Agent is represented in Switzerland by Walder Wyss Ltd., Seefeldstrasse 123, 8008 Zurich (Attn [*Partner*]).

We herewith kindly ask you to register this pledge in the international trademark register. For this purpose, we hereto enclose the duly filled out form[s] [MM 19] and would be pleased if you could send a confirmation of the registration of the pledge in the international trademark register to us and also to the aforementioned representative of the Security Agent.

Yours faithfully

[the Pledgor]

 Name:

Title:

 Name:

Title:

Annexes: the Agreement and Forms MM19 WIPO

Schedule 2b: Form of Notification Letter to Swiss Federal Institute of Intellectual Property (trademarks)

Einschreiben

Institut für Geistiges Eigentum
Stauffacherstrasse 65/59g
3003 Bern

Verpfändung von Marken

Sehr geehrte Damen und Herren

Wir zeigen Ihnen hiermit an, dass wir unsere Marken

[Nos. of Swiss Trademarks]

an

[Name and address of Security Agent], und die von ihr vertretenen Gläubiger,

in der Schweiz vertreten durch:

Walder Wyss AG, *[Partner]*, Seefeldstrasse 123, 8008 Zürich, als hiesiger Vertreter der Pfandgläubiger,

verpfändet haben.

Wir ersuchen Sie um Eintragung des Pfandrechts über die genannten Marken im Schweizerischen Markenregister und die Zustellung einer Eintragungsbestätigung an die hiesigen Vertreter der Pfandgläubigerin.

Mit freundlichen Grüssen

[Name des Pledgors]

Name:

Titel:

Name:

Titel:

Schedule 2c: Form of Notification Letter to Swiss Federal Institute of Intellectual Property (patents)

Einschreiben

Institut für Geistiges Eigentum
Stauffacherstrasse 65/59g
3003 Bern

Verpfändung von Patenten

Sehr geehrte Damen und Herren

Wir zeigen Ihnen hiermit an, dass wir unsere Anteile am schweizerischen und liechtensteinischen Teil der europäischen Patente

[No. of European Patent effective in Switzerland]

an

[Name and address of Pledgee],

in der Schweiz und Liechtenstein vertreten durch:

Walder Wyss AG, *[Partner]*, Seefeldstrasse 123, 8008 Zürich, als hiesiger Vertreter der Pfandgläubiger,

verpfändet haben.

Wir ersuchen Sie um Eintragung des Pfandrechts über die genannten Anteile im schweizerischen Register für europäische Patente und die Zustellung einer Eintragungsbestätigung an die hiesigen Vertreter der Pfandgläubigerin.

Mit freundlichen Grüssen

[Name des Pledgors]

Name:

Titel:

Name:

Titel: